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Background: Randomized controlled trials indicate that addition of a long-acting muscarinic 
antagonist (LAMA) such as tiotropium may improve asthma control and reduce exacerbation 
risk in patients with poorly controlled asthma, but broader clinical studies are needed to inves-
tigate the effectiveness of LAMA in real-life asthma care.
Methods: Medical records of adults with asthma (aged $18 years) prescribed tiotropium were 
obtained from the UK Optimum Patient Care Research Database for the period 2001–2013. 
Patients diagnosed with chronic obstructive pulmonary disease were excluded, but no other 
clinical exclusions were applied. Two primary outcomes were compared in the year before 
(baseline) and the year after (outcome) addition of tiotropium: exacerbations (asthma-related 
hospital emergency department attendance or inpatient admission, or acute oral corticosteroid 
course) and acute respiratory events (exacerbation or antibiotic prescription with lower respi-
ratory consultation). Secondary outcomes included lung function test results and short-acting 
β
2
 agonist usage. The Wilcoxon signed-rank test was used for variables measured on the interval 
scale, the marginal homogeneity test for categorized variables, and the paired t-test for lung 
function indices.
Results: Of the 2,042 study patients, 83% were prescribed an inhaled corticosteroid and 68% 
a long-acting β
2
 agonist during the baseline year; 67% were prescribed both. Comparing base-
line and outcome years, the percentage of patients having at least one exacerbation decreased 
from 37% to 27% (P,0.001) and the percentage having at least one acute respiratory event 
decreased from 58% to 47% (P,0.001). There were no significant changes in lung function, 
and usage of short-acting β
2
 agonists (in salbutamol/albuterol equivalents) increased from a 
median (interquartile range) of 274 (110, 548) to 329 (110, 603) µg/day (P=0.01).
Conclusion: In this real-life asthma population, addition of LAMA therapy was associated 
with significant decreases in the incidence of exacerbations and antibiotic prescriptions for 
lower respiratory tract infections in the following year.
Keywords:  anticholinergic, bronchodilator, exacerbation, asthma control, oral 
corticosteroids
Introduction
Tiotropium bromide is an anticholinergic drug, categorized as a long-acting muscarinic 
antagonist (LAMA) or long-acting anticholinergic bronchodilator.1 These drugs are 
used primarily in the management of chronic obstructive pulmonary disease (COPD), 
but interest in LAMA for the treatment of asthma has increased in recent years, par-
ticularly for patients whose asthma is poorly controlled with inhaled corticosteroids 
(ICS) and long-acting β
2
 agonists (LABA).1–4 Despite clear guidelines and a range 
of available treatments, at least 50% of asthma patients continue to experience poor 
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control of their current symptoms or future exacerbations, 
which significantly compromises the patient’s quality of life 
and places considerable strain on health care systems.1,4 Thus, 
there is a need for additional therapeutic options.
The mechanisms by which LAMA have the potential 
to improve asthma control have recently been reviewed.1 
Briefly, LAMA may: induce bronchodilation, or inhibit 
cholinergically-mediated bronchoconstriction, and with 
regular use inhibit the airway smooth muscle hypertrophy 
and hyper-responsiveness characteristic of chronic asthma; 
reduce cholinergically-mediated mucus secretion and inhibit 
goblet cell hyperplasia and mucus gland hypertrophy; and 
moderate leukocyte responses in the lower airways as well as 
proinflammatory gene expression by airway smooth muscle 
and bronchial epithelium. In addition, LAMA such as tiotro-
pium may act as steroid-sparing agents in patients with severe 
or poorly controlled asthma,5,6 which may alleviate some of 
the burden of corticosteroid use on health-related quality of 
life in these patients.7
A formulation of tiotropium delivered by soft mist inhaler 
has recently been approved in the UK8 and in several other 
countries for add-on maintenance therapy in adults with 
asthma, specifically for patients who are currently treated 
with ICS and LABA yet experienced at least one severe exac-
erbation in the past year. Regulatory approval was based on 
the results of randomized controlled trials (RCTs) in patients 
with asthma which showed that addition of tiotropium to the 
existing controller regimen (ICS ± LABA) improved lung 
function,2,3,9–13 and may improve symptom control3,11,13 and 
lower the patient’s exacerbation risk,3 although it did not 
alter the use of rescue medications such as short-acting β
2
 
agonists (SABAs).2,3,10,13
However, these RCTs involved highly selected patient 
populations (for example, nonsmokers with no serious 
comorbidities) managed in tightly controlled settings, in most 
cases with relatively small patient numbers and short study 
periods.2,9–13 Their broader applicability requires the support 
of clinical studies that better represent real-life populations 
and situations.14 Clinical studies on the effectiveness of 
LAMA as add-on therapy in real-life asthma care are still 
needed.
To that end, we examined the clinical effects of 
add-on therapy with tiotropium in a diverse group of over 
2,000 asthma patients treated in UK primary care  practice. 
Study patients were at least 18 years of age and had a 
physician-recorded diagnosis of asthma; patients with a 
recorded diagnosis of COPD were excluded, but no other 
clinically relevant exclusions were applied. By comparing 
exacerbation rates and other measures of asthma control in 
the year before and after the addition of tiotropium to the 
patient’s asthma regimen, our goal was to determine whether 
the addition of LAMA improves asthma control in routine 
clinical practice.
Materials and methods
This historical, observational study of UK asthma patients 
used data obtained from the Optimum Patient Care Research 
Database (OPCRD; http://www.optimumpatientcare.org), 
which contains more than 5 million anonymized, longitudinal 
patient records from approximately 400 participating medical 
practices in the UK and is focused on patients with evidence 
of respiratory disease. The OPCRD has been approved by 
the Trent Multicentre Research Ethics Committee for use in 
clinical research, and the protocol for this study was approved 
by the Anonymised Data Ethics Protocols and Transparency 
Committee, which is the independent scientific advisory 
committee for the OPCRD.
Data were examined for the period 2001–2013. The 
medical record of each study patient was examined for the 
12 months before (baseline) and 12 months after (outcome) 
the date of the patient’s first prescription for tiotropium 
(index prescription date); hence, the index prescription dates 
spanned 2002–2012. Other LAMA drugs became available in 
the UK towards the end of the study period, but in the inter-
est of investigating LAMA use in as many asthma patients 
as possible while using well-defined criteria, we limited the 
index prescription to tiotropium.
Two formulations of tiotropium bromide for inhalation 
were available in the UK during the study period: a dry-
powder inhaler with a recommended dosage of 10 µg (the 
dose delivered from one 18 µg capsule) once a day15 and a 
soft mist inhaler with a recommended dosage of 5 µg (two 
puffs of 2.5 µg) once a day.8 Although equivalence data are 
not yet available for patients with asthma, these formula-
tions and dosages have comparable bronchodilator efficacy 
in patients with COPD,16,17 so we chose to study the patients 
as a group, regardless of formulation/dosage.
The study patients had at least one prescription for tiotro-
pium during the study window, had a recorded diagnosis 
of asthma, had no recorded diagnosis of COPD, were at 
least 18 years of age at the index prescription date, and had 
two continuous years of data (12 months each of baseline 
and outcome data). Figure 1 illustrates the patient selection 
process and study design.
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Potential patients
n=1,026,936
A. Tiotropium script
n=35,230
B. Asthma diagnosis
n=17,229
C. No COPD diagnosis
n=3,226
D. Age 18+ years
n=3,263
Age <18 years
n=3
COPD diagnosis
n=13,963
No asthma diagnosis
n=18,001
No tiotropium script
n=991,706
Excluded if
E. Full year of baseline
and outcome data
n=2,042
Incomplete baseline
or outcome data
n=1,221
First
tiotropium script
Baseline year Outcome year
Figure 1 Patient selection process and study design. inclusion criteria: (A) at least one prescription for tiotropium, (B) recorded diagnosis of asthma, (C) no recorded diagnosis 
of cOPD, (D) at least 18 years of age at first tiotropium prescription, and (E) full 12 months of data before (baseline) and after (outcome) first tiotropium prescription.
Abbreviation: cOPD, chronic obstructive pulmonary disease.
effectiveness measures
The baseline year was used for patient characterization and the 
outcome year for evaluation of asthma-related effectiveness 
measures. A complete list of the baseline variables examined 
is provided in the Supplementary materials (Table S1), along 
with their definitions and methods of calculation.
The effectiveness measures compared before and after 
addition of tiotropium are described in Table 1. The two 
primary outcomes were exacerbations and acute respiratory 
events. We used the American Thoracic Society and European 
Respiratory Society definition of an exacerbation (asthma-
related urgent hospital attendance/admission or acute course 
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Table 1 effectiveness measures compared before and after 
addition of tiotropium
Variable Definition
Primary
 exacerbations Number of exacerbations, defined as 
occurrence of one of the following: 
1.  Asthma-related urgent hospital visit (A&e or 
inpatient)
2.  Acute Ocs course with evidence of lrT 
consultationa
  Acute respiratory  
events
Number of events, defined as occurrence of 
one of the following:
1.  exacerbation
2.  Antibiotic prescription with evidence of lrT 
consultationa
secondary
  risk domain of  
asthma control
controlled/uncontrolled
controlled if absence of all the following:
1.  Asthma-related hospital visit (A&e, inpatient, 
or outpatient)
2.  Acute Ocs course with evidence of lrT 
consultationa
3.  Antibiotic prescription with evidence of lrT 
consultationa
Uncontrolled if any such events occurred in the 
year of interest
  Acute Ocs  
courses
number of acute Ocs courses with evidence of 
lrT consultationa
  Antibiotic  
prescriptions
number of antibiotic prescriptions with 
evidence of lrT consultationa
  PeF (% predicted)b Peak expiratory flow (PEF), expressed as 
percentage of predicted normal
  FeV1 (% predicted)
b Forced expiratory volume in one second (FeV1), 
expressed as percentage of predicted normal
  FeV1/FVc ratio
b ratio of FeV1 to forced vital capacity (FVc)
  sABA usage Prescribed sABA dosage, averaged over the 
year of interest, in salbutamol (albuterol) 
equivalents
Notes: aAny lower respiratory consultation (asthma, cOPD, or lrT infection 
code, or lung function/asthma monitoring) with additional respiratory examinations, 
including chest X-rays and referrals; bwhen paired baseline and outcome data were 
available.
Abbreviations: A&e, Accident and emergency Department; cOPD, chronic 
obstructive pulmonary disease; lrT, lower respiratory tract; Ocs, oral corticosteroid; 
sABA, short-acting β2 agonist.
of systemic corticosteroids),18 although we limited systemic 
corticosteroid use to an acute course of oral corticosteroids 
(OCS) accompanied by a lower respiratory consultation 
(physician visit coded as asthma, COPD, lower respiratory 
tract infection, or lung function/asthma monitoring, with 
further respiratory examination, thoracic radiographs, or 
referral). An acute respiratory event was defined as either an 
exacerbation or an antibiotic prescription accompanied by a 
lower respiratory consultation (which was taken to indicate 
that the physician treated the episode as a lower respiratory 
tract infection). Multiple qualifying events within a 2-week 
window were counted as a single  exacerbation or acute 
respiratory event.
Secondary measures included the risk domain of asthma 
control (a proxy measure of asthma control as it pertains to 
exacerbation risk), specific components of the primary effec-
tiveness measures (asthma-related acute OCS and antibiotic 
use), peak expiratory flow (PEF), forced expiratory volume in 
one second (FEV
1
), the ratio of FEV
1
 to forced vital capacity 
(FVC), and SABA usage. Asthma control in the risk domain 
was achieved if there were no episodes of asthma-related 
hospital, OCS, or antibiotic usage in the year of interest. As 
the measure of SABA usage, the prescribed SABA dosage 
was averaged over the year of interest, with all SABA dosages 
converted to salbutamol (albuterol) equivalents (Table S1).
statistical analysis
The statistical analysis was conducted using Statistical 
Package for the Social Sciences version 21 software (IBM 
Corporation, Armonk, NY, USA) and Microsoft Excel 2007 
(Microsoft Corporation, Redmond, WA, USA). Statistical 
significance was defined as P,0.05. Mean values are pre-
sented with their standard deviations and median values with 
their interquartile ranges (25th and 75th percentiles). Where 
data were not normally distributed, median (interquartile 
range) values are reported.
Summary statistics were generated for all baseline and 
outcome variables. The number of exacerbations in the year 
before and after initiating tiotropium was then compared 
using the Wilcoxon signed-rank test for exacerbation counts 
measured on the interval scale and the marginal homogeneity 
test for categorized exacerbation data. These tests were also 
used to compare baseline and outcome years for acute respira-
tory events, acute OCS courses, antibiotic prescriptions, and 
SABA usage. The paired t-test was used to compare baseline 
and outcome years for PEF and FEV
1
, and the marginal 
homogeneity test was used for comparison of categorized 
FEV
1
/FVC ratios. The proportion of patients achieving 
asthma control in the risk domain was compared between 
baseline and outcome years using the McNemar test.
sensitivity analysis
Although the selection process deliberately excluded asthma 
patients who also had a recorded diagnosis of COPD, some 
patients with undiagnosed or unrecorded COPD may have 
been included, given the average age of the study patients 
and the prevalence of current or former smokers. For this 
reason, the primary analyses (exacerbations and acute 
respiratory events) were repeated for a subset of patients 
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who were unlikely to have COPD based on the  following 
criteria: #40 years of age, .40 years of age but never 
smoked, and .40 years of age with no evidence of airway 
obstruction (baseline FEV
1
/FVC ratio $0.7).
Results
A total of 2,042 patients met the study criteria. The dry 
powder formulation of tiotropium was prescribed in 
1,898 patients (93%) and the soft mist inhaler in 144 patients 
(7%). Key baseline patient characteristics are summarized 
in Tables 2 and 3; complete baseline data are provided in 
the Supplementary materials (Tables S2–S6). The mean age 
was 63 years; 59% of patients were female; the mean body 
mass index was 29 kg/m2; and of those whose smoking his-
tory was known, 54% were either current (17%) or former 
(37%) smokers. In the patients with baseline lung function 
data, the mean PEF was 69% of predicted normal, the mean 
Table 2 Key descriptive characteristics at baseline
Age (years)
 Mean (sD) 63.4 (14.2)
 .40 years, n (%) 1,906 (93.3%)
gender, female; n (%) 1,208 (59.2%)
BMi (kg/m2); n (%) 1,959 (95.6%)
 Mean (sD) 29.2 (6.7)
 Overweight, n (%) 664 (33.9%)a
 Obese, n (%) 765 (39.1%)a
smoking status, known; n (%) 1,853 (90.7%)
 nonsmoker 849 (45.8%)a
 current smoker 322 (17.4%)a
 ex-smoker 682 (36.8%)a
PeF (% predicted), n (%) 1,358 (66.5%)
 Mean (sD) 69.3 (21.8)
FeV1 (% predicted), n (%) 848 (41.5%)
 Mean (sD) 59.0 (29.0)
FeV1/FVc ratio, n (%) 780 (38.2%)
 Mean (sD) 0.61 (0.24)
 $0.7, n (%) 311 (39.9%)a
ics prescribed, n (%) 1,690 (82.8%)
lABA prescribed, n (%) 1,385 (67.8%)
Adherence to ics (%), n (%) 1,690 (82.8%)
 Median (iQr) 100 (73, 134)
controller-reliever ratio, n (%) 1,909 (93.5%)
 Median (iQr) 0.50 (0.33, 0.71)
hospitalization, $1b; n (%)
 A&e 25 (1.2%)
 inpatient 22 (1.1%)
 Outpatient 22 (1.1%)
Notes: n=2,042, unless otherwise noted; apercentage of patients with data for 
that variable; bat least one asthma-related hospital visit during baseline year 
(categorized).
Abbreviations: A&e, Accident and emergency Department; BMi, body mass index; 
FeV1, forced expiratory volume in one second, expressed as percentage of predicted 
normal; FVc, forced vital capacity; ics, inhaled corticosteroid; iQr, interquartile 
range; lABA, long-acting β2 agonist; PEF, peak expiratory flow, expressed as 
percentage of predicted normal; sD, standard deviation.
Table 3 comparison of effectiveness measures before (baseline) 
and after (outcome) addition of tiotropium
Baseline Outcome P-valuea
exacerbations
 $1, n (%) 752 (36.8%) 543 (26.6%) ,0.001
Acute respiratory events
 $1, n (%) 1,191 (58.3%) 965 (47.3%) ,0.001
risk domain of asthma  
control
 controlled, n (%) 846 (41.4%) 1,071 (52.4%) ,0.001b
Acute Ocs courses
 $1, n (%) 732 (35.8%) 521 (25.5%) ,0.001
Antibiotic prescriptions
 $1, n (%) 1,043 (51.1%) 842 (41.2%) ,0.001
PeF (% predicted), n (%) 926 (45.3%) 926 (45.3%)
 Mean (sD) 70.0 (21.5) 69.5 (21.7) 0.371c
FeV1 (% predicted), n (%) 398 (19.5%) 398 (19.5%)
 Mean (sD) 58.0 (29.5) 57.9 (30.5) 0.935c
FeV1/FVc ratio, n (%) 353 (17.3%) 353 (17.3%)
 ,0.5, n (%)d 91 (25.8%) 116 (32.9%) 0.382
 0.5–0.69, n (%)d 122 (34.6%) 86 (24.4%)
 $0.7, n (%)d 140 (39.7%) 151 (42.8%)
sABA usage (µg/day)e
 Median (iQr) 274 (110, 548) 329 (110, 603) 0.010f
Notes: n=2,042 unless otherwise noted; amarginal homogeneity test, unless 
otherwise noted; bMcnemar test; cpaired t-test; dpercentage of 353 patients with 
paired FeV1/FVc ratio data; 
ein salbutamol (albuterol) equivalents; fWilcoxon signed-
rank test.
Abbreviations: FeV1, forced expiratory volume in one second, expressed as 
percentage of predicted normal; FVc, forced vital capacity; iQr, interquartile range; 
OCS, oral corticosteroid; PEF, peak expiratory flow, expressed as percentage of 
predicted normal; sABA, short-acting β2 agonist; sD, standard deviation.
FEV
1
 was 59% of predicted normal, and the mean FEV
1
/FVC 
ratio was 0.61; only 40% of the patients with FEV
1
 and FVC 
data had a ratio $0.7.
At baseline, most patients were being treated according to 
British Thoracic Society guidelines19 step 3 (21.5%) or step 4 
(49.5%; Table S5). An ICS was prescribed in 83% of patients 
and a LABA in 68% of patients; 67% were prescribed both 
(Table S5). Median adherence to ICS therapy (Table S1) 
was 100%, with 51% of patients having $100% adherence 
(Table S5). The median controller-reliever ratio (Table S1) 
was 0.5, indicating approximately equal use of controller (ICS 
or leukotriene receptor antagonist) and reliever (SABA) medi-
cations, although 59% of patients had a ratio $0.5 (Table S5), 
indicating relatively more controller than reliever use. During 
their baseline year, 37% of patients had at least one exacerba-
tion, 58% had at least one acute respiratory event, and 41% 
achieved asthma control in the risk domain (Table 3).
Outcomes
Comparisons between baseline and outcome years for the 
various effectiveness measures are summarized in Table 3 
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and illustrated in Figures 2–4, with further details provided 
in Table S6. Addition of tiotropium was associated with 
significantly fewer exacerbations (Figure 2) and acute respi-
ratory events (Figure 3); 27% of patients had at least one 
exacerbation, 47% had at least one acute respiratory event, 
and 52% achieved asthma control in the risk domain during 
the outcome year (Table 3). In addition, tiotropium use was 
associated with significantly less asthma-related acute OCS 
and antibiotic use (Tables 3 and S6). Comparing baseline 
and outcome years, SABA usage significantly increased 
(Figure 4), but there were no significant changes in PEF, 
FEV
1
, or FEV
1
/FVC ratio in the patients with paired baseline 
and outcome data for those variables (Table 3).
sensitivity analysis
The sensitivity analysis was conducted on 928 patients 
(45% of the full study group) with the least likelihood of 
also having COPD. Baseline characteristics are summarized 
in Table 4, distributed by age group (#40 and .40 years). 
Compared with the full study group, proportionately more 
patients in this subset were female (65%) and nonsmok-
ers (76%), and fewer were current (9%) or former (15%) 
smokers. The mean FEV
1
/FVC ratio was 0.8. The rates of 
exacerbations and acute respiratory events during the baseline 
year were comparable with those of the full study group, 
and the addition of tiotropium was associated with a similar 
decrease in exacerbations and acute respiratory events during 
the outcome year (Tables 5 and S7).
Discussion
Our study showed that primary care physicians in the UK 
have been prescribing LAMA for the treatment of asthma 
since 2002, even though there were no UK license or guide-
line recommendations for LAMA use in patients with asthma 
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Figure 2 exacerbation rates before (baseline) and after (outcome) addition of 
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years.
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Figure 4 sABA usage before (baseline) and after (outcome) addition of tiotropium. 
Dosages are in salbutamol (albuterol) equivalents; P=0.006 (marginal homogeneity 
test) comparing baseline and outcome years.
Abbreviation: sABA, short-acting β2 agonist.
until September 2014.15 It was not possible with our study 
design to determine why a LAMA was prescribed in these 
patients. However, 93% of the patients were over 40 years 
of age and 62% were over 60 years of age, more than 50% 
of whom were current or former smokers (Table S3). Most 
had significant comorbidities (Table S2), and many had 
impairments of lung function and asthma control in the risk 
domain despite treatment with moderate to high doses of 
ICS ± LABA, $100% adherence to their ICS prescriptions, 
and controller-reliever ratios indicative of equal or greater use 
of controller medications throughout the year. Thus, it appears 
that physicians were prescribing LAMA predominantly 
as add-on therapy in older patients with poorly controlled 
asthma despite good treatment compliance, particularly in 
those who were current or former smokers.
In this population, addition of tiotropium was associated 
with a significant decrease in the incidence of exacerbations 
and other acute respiratory events (specifically, antibiotic 
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Table 4 sensitivity analysis: baseline patient characteristics
Variable Total Age  
#40 years
Age  
.40 years
Age (years), n (%) 928 (100%) 136 (14.7%) 792 (85.3%)
 Mean (sD) 61.3 (16.3) 33.6 (5.8) 66.1 (12.2)
gender, female; n (%) 601 (64.8%) 97 (16.1%) 504 (83.9%)
smoking status, known;  
n (%)
884 (95.3%) 123 (13.9%)a 761 (86.1%)a
 nonsmoker 674 (76.2%)b 58 (8.6%) 616 (91.4%)
 current smoker 79 (8.9%)b 39 (49.4%) 40 (50.6%)
 ex-smoker 131 (14.8%)b 26 (19.8%) 105 (80.2%)
PeF (% predicted); n (%) 615 (66.3%) 89 (14.5%) 526 (85.5%)
 Mean (sD) 72.8 (22.1) 67.4 (20.1) 73.7 (22.3)
FeV1 (% predicted); n (%) 351 (37.8%) 43 (12.3%) 308 (87.7%)
 Mean (sD) 74.9 (27.5) 59.6 (25.2) 77.0 (27.2)
FeV1/FVc ratio, n (%) 328 (35.3%) 40 (12.2%) 288 (87.8%)
 Mean (sD) 0.8 (0.2) 0.7 (0.3) 0.8 (0.2)
Notes: aWithin-row percentages for the two age groups represent percentage of 
the total number of patients in that row; bpercentage of 884 patients whose smoking 
status was known.
Abbreviations: FeV1, forced expiratory volume in one second, expressed as 
percentage of predicted normal; FVc, forced vital capacity; PeF, peak expiratory 
flow, expressed as percentage of predicted normal; SD, standard deviation.
Table 5 sensitivity analysis: comparison of primary measures 
before (baseline) and after (outcome) addition of tiotropium
Variable Baseline Outcome P-valuea
exacerbations
 $1, n (%) 363 (39.1%) 274 (29.5%) ,0.001
Acute respiratory events
 $1, n (%) 567 (61.1%) 452 (48.7%) ,0.001
Notes: n=928; amarginal homogeneity test.
prescriptions for lower respiratory tract infection), and 
a significant increase in the rate of asthma control in the 
risk domain over the following year. Whereas most of the 
aforementioned clinical trials emphasized current symptom 
control, our study was focused primarily on the effects of 
LAMA on the patient’s exacerbation risk, as exacerbations 
have such a negative impact on the patient’s quality of life 
and on health care resources.20 The RCT by Kerstjens et al3 
showed a significant reduction in exacerbation risk with the 
addition of tiotropium; however, their patient population 
was younger than our study group by about 10 years (mean 
age, 53 years), 76% of their patients had never smoked, 
the remainder had a smoking history of ,10 pack-years, 
and none of their patients had serious coexisting illnesses. 
Thus, it may be particularly noteworthy that in our study 
LAMA therapy was associated with a decrease in exacerba-
tions even under less-than-ideal conditions. Also of note, 
LAMA use in our study was associated with a significant 
reduction in acute OCS use, which may be expected to 
reduce the multifaceted treatment burden documented for 
corticosteroid use in patients with severe or poorly con-
trolled asthma.7
Given our study design, it may be argued that regression 
toward the mean could have contributed to the differences 
found between baseline and outcome years. This issue may 
have been obviated by using a matched control group not 
prescribed tiotropium, although such an approach would 
almost certainly have led to the loss of unmatched but oth-
erwise qualified patients prescribed tiotropium and thus to a 
smaller number and perhaps less diverse group of patients for 
study. As it was, our study design involved data collected over 
2 consecutive years within a continuum of ongoing therapy in 
long-term asthma patients that, for the group, spanned over 
a decade (2001–2013); and with the exception of the lung 
function indices, the baseline and outcome values each rep-
resented a full year of data, not repeated measures of single, 
isolated points in time. Thus, if regression toward the mean 
was a factor in our study results, its influence was likely small. 
Furthermore, our findings are supported by those of Kerstjens 
et al,3 who showed in two replicate, randomized, double-blind, 
placebo-controlled, parallel-group clinical trials involving 
48-week study periods and 912 patients in 15 countries that 
addition of tiotropium significantly increased the time to first 
exacerbation and decreased the exacerbation risk in patients 
whose asthma was poorly controlled despite maintenance 
treatment with ICS and LABA.
A legitimate concern, given our study design and patient 
demographics, is that the group may have included some 
asthma patients who also had undiagnosed or unrecorded 
COPD. The sensitivity analysis, limited to the patients least 
likely to have COPD, was conducted to address this issue. 
In this subset, addition of tiotropium was associated with 
decreases in the incidence of exacerbations and other acute 
respiratory events (specifically, antibiotic prescriptions 
for lower respiratory tract infection) similar to that found 
in the full study group. Thus, it is reasonable to conclude 
that LAMA therapy may be associated with a decrease in 
asthma exacerbations whether or not the patient may also 
have COPD.
A further criticism is that no separate control or compara-
tor group was included, and treatment was not randomized. 
Our study purpose was to retrospectively examine the out-
comes of clinical decisions made by primary care physicians 
with regard to the use of LAMA therapy in real-life patients 
with asthma. There was therefore no opportunity for us to 
randomize treatment, and as discussed above, our decision 
not to include a matched control group was made deliber-
ately and with the goal of generating as large and diverse a 
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treatment group as possible. Thus, our study patients served 
as their own controls, the comparisons in asthma-related 
effectiveness measures being made between the year before 
and the year after initiating LAMA therapy. Despite this and 
other limitations imposed by our study design, our findings 
are generally consistent with those of the RCTs that included 
placebo2,3,9–12 or comparator drug groups.10,13
Yet another potential shortcoming of our study design 
is that not all study patients had lung function data, and in 
those who did, no constraints could be placed on the timing 
of the lung function tests with regard to time of day (morn-
ing or evening) or bronchodilator administration (before 
or after bronchodilation), when the tests were performed 
in the outcome year relative to initiation of tiotropium 
therapy, nor on quality control of the measurements. In 
comparison, licensing studies require centralized spirometry 
over-reading to ensure high quality spirometry. In order to 
maximize patient numbers, we elected not to limit the study 
group to only those patients with paired lung function data. 
Physicians evidently were prescribing LAMA for patients 
with asthma even in the absence of lung function tests, so 
our full study group reflects recent clinical practices and 
outcomes.
The inability to dictate the timing and performance of 
the lung function tests in our study likely contributed to the 
large variations found in lung function values. Along with 
patient age and inclusion of smokers, that may explain the 
lack of significant changes in lung function with the addition 
of tiotropium, when improvements in lung function were a 
consistent RCT finding.2,3,9–13 It is worth noting, however, that 
the RCT improvements in lung function with the addition of 
tiotropium, while statistically significant, often were small, 
and they were not consistently accompanied by improve-
ments in asthma control or quality of life.2,3,9,12,13
Between baseline and outcome years, the change in SABA 
usage in our study group, while statistically significant, was 
small and may be considered of little clinical relevance. This 
finding is consistent with RCT results for tiotropium use in 
patients with asthma,2,3,10,13 but it is somewhat at odds with 
the classification of tiotropium as a long-acting bronchodila-
tor that is administered once daily,8,15 and with the proposed 
mechanisms by which LAMA may improve asthma control.1 
A longer investigation period may be required to determine 
whether or not LAMA perform in practice as these mecha-
nisms propose. In the meantime, it is useful to know that 
addition of tiotropium to the current treatment regimen may 
reduce the asthma patient’s exacerbation risk within the first 
year of treatment.
Conclusion
In this real-life population of adults with asthma treated in 
routine clinical practice, addition of a LAMA to the current 
treatment regimen was associated with a decrease in exac-
erbations and other acute respiratory events (specifically, 
antibiotic prescriptions for lower respiratory tract infections) 
in the following year.
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Supplementary materials
Table S1 Baseline variables examined
Variable Description
Variables examined at, or closest to, the index prescription date:a
 Age in years; also categorized as 18–40, 41–60, or .60 years
 gender Male or female
 Body mass index in kg/m2; categorized as underweight (,18.5), normal (18.5–24.9), overweight (25–29.9), or obese ($30)
 smoking status nonsmoker, current smoker, ex-smoker, or unknown
 PeF, % predicted Predicted normal PeF (l/sec) was calculated as follows: for men, (5.317× height [m]) - (0.062× age [years]) +3.884; for 
women, (4.087× height [m]) - (0.05× age [years]) +2.945; the patient’s PeF reading was compared with the predicted 
value and expressed as a percentage of predicted normal
 FeV1, % predicted Predicted normal FeV1 (l) was calculated as follows: for men, (4.3× height [m]) - (0.029 × age [years]) -2.49; for women, 
(3.95× height [m]) - (0.025× age [years]) -2.6; for both, 25 years was used for age in patients 18–25 years; the patient’s 
FeV1 reading was compared with the predicted value and expressed as a percentage of predicted normal
 FVc Used to calculate FeV1/FVc ratio; also categorized as ,0.5, 0.5–0.69, or $0.7
Variables examined regardless of when they occurred relative to index prescription date:a
 First asthma diagnosis Date when asthma first diagnosed (if known)
 comorbidities Including rhinitis (or prescription for rhinitis nasal spray), gastroesophageal reflux disease, and cardiac disease  
(or prescription for cardiac drugs)
  charlson comorbidity  
index scoreb
categorized as 0, 1–4, or 5+
Variables examined in the year before the index prescription date:a
  respiratory  
treatments
All asthma, allergy, and other respiratory treatments
 ics usage Where ics prescribed, number of inhalers, dosage, and average daily dosage (averaged over the year); all ics dosages 
are in FP equivalents: large-particle BDP and budesonide dosages were divided by 2 to yield the FP-equivalent dosage; 
extra-fine particle BDP and ciclesonide dosages were considered directly equivalent to FP dosages for this study
  general practice 
consultations
number of general practice consultations, total and asthma-related
 Acute Ocs courses number of acute Ocs courses accompanied by lower respiratory consultation;c total and categorized as 0, 1, 2, or 3+
 BTs step Treatment step (1–5), as described by BTs guidelines;d step 0 was added to denote patients prescribed no asthma 
treatment
 hospitalization number of asthma-related A&e attendances, inpatient admissions, or outpatient visits
 sABA usage Prescribed sABA dosage, averaged over the year: ([number of inhalers × doses per inhaler] ÷365) × strength (µg); all 
sABA dosages are in salbutamol (albuterol) equivalents: terbutaline dosages were divided by 2.5 to yield the salbutamol-
equivalent dosage; average daily dosage and categorized as 0, 1–200, 201–400, or .400 µg/day
  risk domain  
of asthma control
A composite proxy measure of exacerbation risk (see text); controlled or uncontrolled
  Antibiotic  
prescriptions
number of antibiotic prescriptions accompanied by lower respiratory consultation;c total and categorized as 0, 1, 2, or 3+
 Other medications Prescription for β-blockers, nsAiDs, paracetamol (acetaminophen), tricyclic antidepressants, and statins
 exacerbations number of asthma exacerbations (see text); total and categorized as 0, 1, 2, or 3+
  Acute respiratory  
events
number of acute events (see text); total and categorized as 0, 1, 2, or 3+
  Adherence to  
ics therapy
Adherence (%) = (total pack days ÷365) ×100; where total pack days = sum (number of days/pack), and days/pack = 
actuations/pack ÷ actuations/day
  controller-reliever  
ratio
calculated as units of controllers ÷ (units of controllers + units of relievers); controllers included ics and lTrA,  
one unit = one inhaler for ics or one prescription for lTrA; relievers were limited to sABA, one unit = one inhaler; 
lABA were excluded from this analysis, as ics-lABA combination inhalers would have skewed the results
Notes: aDate of the patient’s first tiotropium prescription; bAylin P, Bottle A, Jen Mh, et al. hsMr mortality indicators. london, UK: Doctor Foster research; 2010. Available 
from: http://www.nhs.uk/scorecard/Documents/hsMr%20methodology%2009%20november.pdf. Accessed on March 15, 2013; cany lower respiratory consultation (asthma, 
cOPD, or lrTi code, or lung function/asthma monitoring) with additional respiratory examinations, chest X-rays, and referrals; dBritish guideline on the Management 
of Asthma. london, UK: British Thoracic society; 2014. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-
guideline-2014/.
Abbreviations: A&e, Accident and emergency Department; BDP, beclomethasone dipropionate; BTs, British Thoracic society; cOPD, chronic obstructive pulmonary 
disease; FeV1, forced expiratory volume in one second; FP, fluticasone propionate; FVC, forced vital capacity; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; 
LTRA, leukotriene receptor antagonist; LRTI, lower respiratory tract infection; NSAIDs, nonsteroidal anti-inflammatory drugs; OCS, oral corticosteroid; PEF, peak expiratory 
flow; SABA, short-acting β2 agonist.
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Table S2 Baseline patient characteristics: demographic and 
clinical variables
Age (years)
 Mean (sD) 63.4 (14.2)
 18–40, n (%) 136 (6.7%)
 41–60, n (%) 637 (31.2%)
 .60, n (%) 1,269 (62.1%)
gender
 Female, n (%) 1,208 (59.2%)
BMi (kg/m2); n (%) 1,959 (95.6%)
 Mean (sD) 29.2 (6.7)
 Underweight (,18.5), n (%) 42 (2.1%)
 normal (18.5–24.9), n (%) 488 (24.9%)
 Overweight (25–29.9), n (%) 664 (33.9%)
 Obese ($30), n (%) 765 (39.1%)
smoking status, n (%)
 nonsmoker 849 (41.6%)
 current smoker 322 (15.8%)
 ex-smoker 682 (33.4%)
 Unknown 189 (9.2%)
PeF (% predicted), n (%) 1,358 (66.5%)
 Mean (sD) 69.3 (21.8)
FeV1 (% predicted), n (%) 848 (41.5%)
 Mean (sD) 59.0 (29.0)
FeV1/FVc ratio, n (%) 780 (38.2%)
 Mean (sD) 0.61 (0.24)
 ,0.5, n (%) 225 (28.8%)
 0.5–0.69, n (%) 244 (31.3%)
 $0.7, n (%) 311 (39.9%)
cci score, n (%)
 0 746 (36.5%)
 1–4 854 (41.8%)
 5+ 442 (21.6%)
comorbidities, n (%)
 rhinitisa 730 (35.7%)
 gerD 301 (14.7%)
 cardiac diseaseb 1,286 (63.0%)
 ischemic heart disease 308 (15.1%)
comedications prescribed, n (%)
 β blocker 127 (6.2%)
 nsAiD 820 (40.2%)
 Paracetamol 906 (44.4%)
 Tricyclic antidepressant 221 (10.8%)
 statin 618 (30.3%)
Notes: n=2,042, unless otherwise noted; adiagnosis at any time or nasal spray 
prescribed during baseline or outcome year; bdiagnosis or cardiac drugs prescribed 
at any time.
Abbreviations: BMi, body mass index; cci, charlson comorbidity index; FeV1, 
forced expiratory volume in one second, expressed as percentage of predicted 
normal; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; NSAID, 
nonsteroidal anti-inflammatory drug; PEF, peak expiratory flow, expressed as 
percentage of predicted normal; sD, standard deviation.
Table S3 Baseline smoking status by age group
Age group Smoking status
Nonsmoker Current  
smoker
Ex- 
smoker
Unknown
18–40 years,  
n (%)
58 (6.8%) 39 (12.1%) 26 (3.8%) 13 (6.9%)
41–60 years,  
n (%)
228 (26.9%) 168 (52.2%) 186 (27.3%) 55 (29.1%)
.60 years,  
n (%)
563 (66.3%) 115 (35.7%) 470 (68.9%) 121 (64.0%)
Total, n (%) 849 (100%) 322 (100%) 682 (100%) 189 (100%)
Table S4 Distribution of baseline FeV1/FVc ratio in patients 
over 60 years of age, by smoking status
FEV1/FVC ratio All Current smokers Ex-smokers
,0.5, n (%) 156 (29.1%) 16 (32.7%) 74 (33.9%)
0.5–0.69, n (%) 176 (32.8%) 19 (38.8%) 64 (29.4%)
$0.7, n (%) 204 (38.1%) 14 (28.6%) 80 (36.7%)
Total, n (%) 536 (100%) 49 (100%) 218 (100%)
Abbreviations: FeV1, forced expiratory volume in one second, expressed as 
percentage of predicted normal; FVc, forced vital capacity.
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Table S5 Baseline patient characteristics: asthma treatment and 
control
sABA inhalers, n
 Median (iQr) 5 (2, 10)
Primary care consultations, n
 Median (iQr) 14 (9, 22)
Asthma consultations,a n
 Median (iQr) 1 (0, 2)
 0, n (%) 664 (32.5%)
 1, n (%) 593 (29.0%)
 2, n (%) 347 (17.0%)
 3+, n (%) 438 (21.4%)
Specific asthma medications, n (%)
 none 117 (5.7%)
 sABA only 149 (7.3%)
 sAAc only 11 (0.5%)
 sABA + sAAc 35 (1.7%)
 lABA ± sABA/sAAc 21 (1.0%)
 ics ± sABA/sAAc 301 (14.7%)
 ics + lABA ± sABA/sAAc 1,055 (51.7%)
 lTrA ± sABA/sAAc 16 (0.8%)
 ics + lTrA ± sABA/sAAc 27 (1.3%)
 ics + lABA + lTrA ± sABA/sAAc 307 (15.0%)
 lABA + lTrA + theophylline ± sABA/sAAc 2 (0.1%)
 Theophylline 1 (,0.1%)
ics inhalers, n
 Median (iQr) 6 (2, 10)
Baseline ics dosage (µg/day)b,c
 Median (iQr) 247 (66, 493)
 0, n (%) 352 (17.2%)
 1–100, n (%) 296 (14.5%)
 101–200, n (%) 311 (15.2%)
 201–400, n (%) 385 (18.9%)
 401–800, n (%) 436 (21.4%)
 .800, n (%) 262 (12.8%)
ics dosage pre-iPD (µg/day),c,d n (%) 1,690 (82.8%)
 Median (iQr) 500 (200, 1,000)
ics dosage at iPD (µg/day),c n (%) 537 (26.3%)
 Median (iQr) 500 (400, 1,000)
Adherence to ics (%), n (%) 1,690 (82.8%)
 Median (iQr) 100 (73, 134)
 ,50%, n (%) 201 (11.9%)
 50%–69.9%, n (%) 185 (10.9%)
 70%–99.9%, n (%) 451 (26.7%)
 $100%, n (%) 853 (50.5%)
controller-reliever ratio, n (%) 1,909 (93.5%)
 Median (iQr) 0.5 (0.3, 0.7)
 ,0.5, n (%) 787 (41.2%)
 $0.5, n (%) 1,122 (58.8%)
lABA prescribed, n (%) 1,385 (67.8%)
spacer device used, n (%) 279 (13.7%)
BTs step, n (%)
 0 118 (5.8%)
 1 212 (10.4%)
 2 252 (12.3%)
 3 439 (21.5%)
 4 1,011 (49.5%)
 5 10 (0.5%)
(Continued)
Table S5 (Continued)
hospitalization, $1e; n (%)
 A&e 25 (1.2%)
 inpatient 22 (1.1%)
 Outpatient 22 (1.1%)
Notes: n=2,042, unless otherwise noted; anonspecialist primary care consultations 
where asthma was recorded; bprescribed ics dosage, averaged over the baseline 
year; cin fluticasone-propionate equivalents; ddosage prescribed at most recent 
consultation before iPD; eat least one asthma-related hospital visit during baseline 
year (categorized).
Abbreviations: A&e, Accident and emergency Department; BTs, British Thoracic 
Society; ICS, inhaled corticosteroid; IPD, index prescription date (date of first 
tiotropium script); iQr, interquartile range; lABA, long-acting β2 agonist; lTrA, 
leukotriene receptor antagonist; sAAc, short-acting anticholinergic; sABA, short-
acting β2 agonist.
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Table S6 comparison of effectiveness measures before (baseline) 
and after (outcome) addition of tiotropium
Variable Baseline Outcome P-value
exacerbations ,0.001a
 Median (iQr) 0 (0, 1) 0 (0, 1)
 0, n (%) 1,290 (63.2%) 1,499 (73.4%) ,0.001b
 1, n (%) 415 (20.3%) 330 (16.2%)
 2, n (%) 180 (8.8%) 116 (5.7%)
 3+, n (%) 157 (7.7%) 97 (4.8%)
Acute respiratory events ,0.001a
 Median (iQr) 1 (0, 2) 0 (0, 1)
 0, n (%) 851 (41.7%) 1,077 (52.7%) ,0.001b
 1, n (%) 498 (24.4%) 506 (24.8%)
 2, n (%) 328 (16.1%) 218 (10.7%)
 3+, n (%) 365 (17.9%) 241 (11.8%)
risk domain of asthma  
control
 controlled, n (%) 846 (41.4%) 1,071 (52.4%) ,0.001c
Acute Ocs courses ,0.001a
 Median (iQr) 0 (0, 1) 0 (0, 1)
 0, n (%) 1,310 (64.2%) 1,521 (74.5%) ,0.001b
 1, n (%) 402 (19.7%) 316 (15.5%)
 2, n (%) 175 (8.6%) 115 (5.6%)
 3+, n (%) 155 (7.6%) 90 (4.4%)
Antibiotic prescriptions ,0.001a
 Median (iQr) 1 (0, 2) 0 (0, 1)
 0, n (%) 999 (48.9%) 1,200 (58.8%) ,0.001b
 1, n (%) 469 (23.0%) 440 (21.5%)
 2, n (%) 268 (13.1%) 196 (9.6%)
 3+, n (%) 306 (15.0%) 206 (10.1%)
PeF (% predicted), n (%) 926 (45.3%) 926 (45.3%)
 Mean (sD) 70.0 (21.5) 69.5 (21.7) 0.371d
FeV1 (% predicted), n (%) 398 (19.5%) 398 (19.5%)
 Mean (sD) 58.0 (29.5) 57.9 (30.5) 0.935d
FeV1/FVc ratio, n (%) 353 (17.3%) 353 (17.3%)
 ,0.5 91 (25.8%) 116 (32.9%) 0.382b
 0.5–0.69 122 (34.6%) 86 (24.4%)
 $0.7 140 (39.7%) 151 (42.8%)
sABA usage (µg/day)e 0.010a
 Median (iQr) 274 (110, 548) 329 (110, 603)
 0, n (%) 327 (16.0%) 317 (15.5%) 0.006b
 1–200, n (%) 493 (24.1%) 450 (22.0%)
 201–400, n (%) 451 (22.1%) 451 (22.1%)
 .400, n (%) 771 (37.8%) 824 (40.4%)
Notes: n=2,042, unless otherwise noted; aWilcoxon signed-rank test; bmarginal 
homogeneity test; cMcnemar test; dpaired t-test; ein salbutamol (albuterol) equivalents.
Abbreviations: FeV1, forced expiratory volume in one second, expressed as 
percentage of predicted normal; FVc, forced vital capacity; iQr, interquartile range; 
OCS, oral corticosteroid; PEF, peak expiratory flow, expressed as percentage of 
predicted normal; sABA, short-acting β2 agonist; sD, standard deviation.
Table S7 sensitivity analysis: comparison of primary measures 
before (baseline) and after (outcome) addition of tiotropium
Variable Baseline Outcome P-value
exacerbations ,0.001a
 Median (iQr) 0 (0, 1) 0 (0, 1)
 0, n (%) 565 (60.9%) 654 (70.5%) ,0.001b
 1, n (%) 198 (21.3%) 167 (18.0%)
 2, n (%) 93 (10.0%) 62 (6.7%)
 3+, n (%) 72 (7.8%) 45 (4.8%)
Acute respiratory events ,0.001a
 Median (iQr) 1 (0, 2) 0 (0, 1)
 0, n (%) 361 (38.9%) 476 (51.3%) ,0.001b
 1, n (%) 231 (24.9%) 228 (24.6%)
 2, n (%) 149 (16.1%) 108 (11.6%)
 3+, n (%) 187 (20.2%) 116 (12.5%)
Notes: n=928; aWilcoxon signed-rank test; bmarginal homogeneity test.
Abbreviation: iQr, interquartile range.
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